Alzheimer’s disease (AD) is a progressive neurodegenerative disease, characterized by β-amyloid (Aβ) plaques, neurofibrillary tangles, gliosis, oxidative stress, neuronal degeneration, and dementia. It was discovered twenty years ago that dysregulation of cellular Ca2+ leads to impaired cognition and increased susceptibility to AD and other neurodegenerative conditions. In particular Ca2+-dependent protein phosphatase calcineurin –a dependent transcription factor, nuclear factor of activated T cells (NFAT) has been implicated in AD and serves as a valid target for AD.
Dr. Khan and colleagues characterized novel engineered fluorescent proteins which allowed the development of both translocation and transcriptional assays. This dual cell-based assay format will enable the discovery of new drugs targeting the NFATc1A signal transduction pathway.
Read the full publication here